Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program

BACKGROUND:Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups. METHODS:The CAN...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2018-07, Vol.138 (5), p.458-468
Main Authors: Rådholm, Karin, Figtree, Gemma, Perkovic, Vlado, Solomon, Scott D, Mahaffey, Kenneth W, de Zeeuw, Dick, Fulcher, Greg, Barrett, Terrance D, Shaw, Wayne, Desai, Mehul, Matthews, David R, Neal, Bruce
Format: Article
Language:English
Subjects:
Aged
Biomarkers - blood
Blood Glucose - drug effects
Blood Glucose - metabolism
Canagliflozin - adverse effects
Canagliflozin - therapeutic use
Cause of Death
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - mortality
Disease Progression
Europe
Female
Heart Failure - diagnosis
Heart Failure - drug therapy
Heart Failure - mortality
Heart Failure - physiopathology
Hospitalization
Humans
Male
Middle Aged
Original s
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Time Factors
Treatment Outcome
United States
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND:Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups. METHODS:The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10 142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. The primary end point for these analyses was adjudicated cardiovascular death or hospitalized HF. RESULTS:Participants with a history of HF at baseline (14.4%) were more frequently women, white, and hypertensive and had a history of prior cardiovascular disease (all P
ISSN:0009-7322
1524-4539
1524-4539
DOI:10.1161/CIRCULATIONAHA.118.034222